» Articles » PMID: 18272844

Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan

Overview
Specialty Nephrology
Date 2008 Feb 15
PMID 18272844
Citations 113
Authors
Affiliations
Soon will be listed here.
Abstract

There is large interindividual variability in the antiproteinuric response to blockade of the renin-angiotensin-aldosterone system (RAAS). A low-sodium diet or addition of diuretics enhances the effects of RAAS blockade on proteinuria and BP, but the efficacy of the combination of these interventions is unknown. Therefore, this randomized, double-blind, placebo-controlled trial to determine the separate and combined effects of a low-sodium diet and hydrochlorothiazide (HCT) on proteinuria and BP was performed. In 34 proteinuric patients without diabetes, mean baseline proteinuria was 3.8 g/d, and this was reduced by 22% by a low-sodium diet alone. Losartan monotherapy reduced proteinuria by 30%, and the addition of a low-sodium diet led to a total reduction by 55% and the addition of HCT to 56%. The combined addition of HCT and a low-sodium diet reduced proteinuria by 70% from baseline (all P < 0.05). Reductions in mean arterial pressure showed a similar pattern (all P < 0.05). In addition, individuals who did not demonstrate an antiproteinuric response to losartan monotherapy did respond when a low-sodium diet or a diuretic was added. In conclusion, a low-sodium diet and HCT are equally efficacious in reducing proteinuria and BP when added to a regimen containing losartan and especially seem to benefit individuals who are resistant to RAAS blockade. Combining these interventions in sodium status is an effective method to maximize the antiproteinuric efficacy of RAAS blockade.

Citing Articles

Guidelines for the management of hypertension in CKD patients: where do we stand in 2024?.

Theodorakopoulou M, Ortiz A, Fernandez-Fernandez B, Kanbay M, Minutolo R, Sarafidis P Clin Kidney J. 2024; 17(Suppl 2):36-50.

PMID: 39583143 PMC: 11581767. DOI: 10.1093/ckj/sfae278.


Effective method for life-style modifications focused on dietary sodium intake in chronic kidney disease: sub-analysis of the FROM-J study.

Kanauchi N, Saito C, Nagai K, Yamada K, Kai H, Watanabe T BMC Nephrol. 2024; 25(1):274.

PMID: 39187778 PMC: 11348764. DOI: 10.1186/s12882-024-03707-7.


A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension.

Sarafidis P, Schmieder R, Burnier M, Persu A, Januszewicz A, Halimi J Nephrol Dial Transplant. 2024; 39(6):929-943.

PMID: 38365947 PMC: 11139525. DOI: 10.1093/ndt/gfae041.


Risk Factors of Chronic Kidney Disease Progression: Between Old and New Concepts.

Mallamaci F, Tripepi G J Clin Med. 2024; 13(3).

PMID: 38337372 PMC: 10856768. DOI: 10.3390/jcm13030678.


Self-Monitoring and Self-Efficacy in Patients with Chronic Kidney Disease During Low-Sodium Diet Self-Management Interventions: Secondary Analysis of the ESMO and SUBLIME Trials.

Hoekstra T, Dam M, Klaassen G, Bos W, van der Boog P, Vogt L Int J Behav Med. 2023; 32(1):34-44.

PMID: 38066237 DOI: 10.1007/s12529-023-10240-8.


References
1.
Kopple J . The National Kidney Foundation K/DOQI clinical practice guidelines for dietary protein intake for chronic dialysis patients. Am J Kidney Dis. 2001; 38(4 Suppl 1):S68-73. DOI: 10.1053/ajkd.2001.27578. View

2.
Wapstra F, van Goor H, Navis G, de Jong P, de Zeeuw D . Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. Clin Sci (Lond). 1996; 90(5):393-401. DOI: 10.1042/cs0900393. View

3.
. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997; 349(9069):1857-63. View

4.
Kang D, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M . A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002; 13(12):2888-97. DOI: 10.1097/01.asn.0000034910.58454.fd. View

5.
Derkx F, Wenting G, Boomsma F, Man in t Veld A, SCHALEKAMP M . Asynchronous changes in prorenin and renin secretion after captopril in patients with renal artery stenosis. Hypertension. 1983; 5(2):244-56. DOI: 10.1161/01.hyp.5.2.244. View